

Veracyte, Inc. Investor Relations Department 6000 Shoreline Court Suite 300 South San Francisco, CA 94080 United States

Visit IR website \square^2 Sign-up for Email alerts \square^2

NASDAQ: VCYT	
Last Trade:	8.08
Trade Time:	4:00 PM ET Jul 25, 2017
Change:	0.02 🕇 (+0.248%)
Day Range	7.94 - 8.23
52-Week Range	4.83 - 9.71
Volume	37,862

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company's products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary. (more)

Stock Performance



Press Releases [View all]

Jul 18, 2017

Veracyte to Host Conference Call and Webcast to Discuss Second Quarter 2017 Financial Results on Monday, July 31, 2017

Jun 27, 2017

Veracyte Announces Publication of Study
Supporting the Development of Envisia™
Genomic Classifier for IPF in Annals of the
American Thoracic Society

Jun 26, 2017

Veracyte Named a San Francisco Bay Area
"Top Workplace" For Fourth Consecutive
Year

Jun 1, 2017

Veracyte to Present at William Blair 2017 Growth Stock Conference

May 23, 2017

Veracyte Announces Clinical Validation Data

Demonstrating Envisia™ Genomic

Classifier's Performance in Improving

Idiopathic Pulmonary Fibrosis Diagnosis

Presented at ATS 2017

Upcoming Events [View all]

Jul 31, 2017 1:30 PM PT

Veracyte Second Quarter 2017 Financial
Results Webcast

Financials [View all]

First Quarter Financial Results

Mar 1, 2017

Annual Report (10-K)

Apr 21, 2017

Proxy Statement (DEF 14A)

May 3, 2017

Quarterly Report (10-Q)

Nov 3, 2016

Quarterly Report (10-Q)

Aug 3, 2016

Quarterly Report (10-Q)